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A B S T R A C T
Pain is a major symptom of bone metastases from advanced cancer and represents a clinical challenge to treat
eﬀectively. Basic neurobiology in preclinical animal models implicates enhanced sensory processing in the
central nervous system, acting through N-methyl-D-aspartate (NMDA) glutamate receptors, as an important
mechanism underpinning persistent pain. The non-receptor tyrosine kinase Src is thought to act as a hub for
regulating NMDA receptor activity and the orally available Src inhibitor saracatinib has shown promise as a
potential analgesic in recent animal studies. Here we tested the eﬃcacy of saracatinib as a novel analgesic in an
exploratory phase II randomized controlled trial on cancer patients with painful bone metastases. Twelve pa-
tients completed the study, with 6 receiving saracatinib 125mg/day for 28 days and 6 receiving placebo.
Pharmacokinetic measurements conﬁrmed appropriate plasma levels of drug in the saracatinib-treated group
and Src inhibition was achieved clinically by a signiﬁcant reduction in the bone resorption biomarker serum
cross-linked C-terminal telopeptide of type I collagen. Diﬀerences between the saracatinib and placebo groups
self-reported pain scores, measured using the short form of the Brief Pain Inventory, were not clinically sig-
niﬁcant after 4 weeks of treatment. There was also no change in consumption of maintenance analgesia in the
saracatinib-treated group and no improvement in Quality-of-Life scores. The data were insuﬃcient to demon-
strate saracatinib has eﬃcacy as analgesic, although it may have a role as an anti-bone resorptive agent.
1. Introduction
Pain from bone metastases is a common feature of advanced cancer,
occurring in approximately 70% of patients with late-stage disease
[1,2]. The four commonest cancers worldwide (lung, breast, bowel,
prostate [3]) all have a predilection to spread to bone, resulting in in-
creased morbidity, not only due to pain, but also from fractures, spinal
cord compression and hypercalcaemia (skeletal-related events). The
innervation of bone and possible neurobiological mechanisms of bone
pain have been comprehensively covered in a recent review [4], but an
emerging feature of cancer-induced bone pain is that it has features of
both neuropathic pain, due to damage to peripheral nerve ﬁbres from
the growing tumour, and inﬂammatory pain, due to tissue acidosis and
local chemokines/cytokines. Chronic pain, including bone pain, is also
associated with changes in central neural processing of nociceptive
information that results in ampliﬁed behavioural responses (central
sensitization [5]). Activation of C-ﬁbres from deep tissues e.g. joint or
muscle is thought to be a much more eﬀective driver of central sensi-
tization than stimulation of cutaneous aﬀerents [6].
The consensus of preclinical laboratory studies is that synaptic
plasticity in spinal cord neurons, particularly increased glutamatergic
excitatory neurotransmission, is thought to be a major mechanism un-
derlying central sensitization that contributes to pain hypersensitivity
[5,7–9]. This form of synaptic plasticity involves activation of G-protein
coupled membrane receptors and intracellular signaling pathways that
are thought to converge on the protein tyrosine kinase Src [10,11];
activation of spinal N-methyl-D-aspartate (NMDA) glutamate receptors
follows, with phosphorylation of the GLUN1 and GluN2B subunits
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being the key molecular drivers [5,10–14]. Blocking Src anchoring with
the NMDA receptor resulted in reduced inﬂammatory and neuropathic
pain hypersensitivity and Src−/− knockout mice showed diminished
central sensitization-mediated nociceptive behaviours but retained
normal nociceptive processing [15]. Controlling Src activity might
therefore be key to reducing NMDA receptor activation and could re-
present a novel analgesic mechanism.
Our recent preclinical studies have shown that the orally-active Src
inhibitor saracatinib (from AstraZeneca, UK) has potential use as an
analgesic in cancer-induced bone pain, as it reversed some of the pain
behaviours evoked by intra-tibial injection of mammary cancer cells in
rats [16]. Saracatinib also inhibits osteoclastic bone resorption [16–18],
which could be useful in the management of patients with skeletal
metastases. In the current study we have tested whether saracatinib has
analgesic eﬃcacy in cancer patients with bone pain due to metastatic
disease.
2. Methods
Prior to opening for recruitment, the study was registered on the
European Clinical Trials database (EudraCT number 2013-00250562).
A favourable ethical opinion was obtained from the local oﬃce
(Yorkshire & The Humber) of the National Research Ethics Committee
of the UK Health Research Authority (13/YH/0623) and clinical trial
authorization was obtained from the UK Medicines and Healthcare
Regulatory Authority (CTA number: 21304/0249/001-001).
2.1. Participants and recruitment
Participants were recruited from either out-patient clinics in a
specialized Oncology Hospital (Weston Park Hospital, Sheﬃeld UK) or
from a palliative care Hospice (St. Gemma's Hospice, Leeds UK).
Potential recruits were identiﬁed by screening clinical records to
identify patients with bone metastases (primary screen) and then at
individual consultations with their Oncologist/Palliative Care physician
(secondary screen) to identify patients that had sub-optimal control of
bone pain with their existing medication. There were no limits on the
type or dose of existing pain relief medications that patients were taking
to be eligible for recruitment and patients taking maintenance che-
motherapy were also able to participate. Patients that had previous/
planned radiotherapy to the site of their pain had to be at least one
month post-treatment to be eligible for recruitment and no new treat-
ments/medications were permitted during the study.
Inclusion criteria were: (1) cytologically or histologically conﬁrmed
solid tumours or multiple myeloma with painful bone metastases and
poor control of bone pain in spite of pain medication. Prostate cancer
patients without histology or cytology were eligible for recruitment if
their prostate speciﬁc antigen was >100 ng/mL at diagnosis and a bone
scan conﬁrmed skeletal metastases; (2) baseline average pain ≥2 and
≤9 on a 0–10 numerical scale recorded on at least two separate days
using the Brief Pain Inventory-Short Form; (3) WHO performance status
≤2; (4) age≥16 years; (5) ability to take and absorb oral medications;
(6) able to give written informed consent and willing to follow the
study protocol; (7) adequate baseline haematological, hepatic and renal
function, which was deﬁned as: Haemoglobin >9.0 g/dL (including
after transfusion), absolute neutrophil count ≥ 1.5×109/L, platelet
count ≥100 × 109/L, bilirubin ≤1.5 x upper limit of normal (ULN),
alanine transaminase or aspartate transaminase ≤2.5 x ULN (≤
5 x ULN if liver metastases), creatinine ≤1.5 x ULN.
Exclusion criteria were: (1) life expectancy <3 months; (2) previous
or planned radiotherapy at site of pain within one month of ﬁrst dose;
(3) unstable cardiac disease in last 3 months; (4) history of interstitial
lung disease; (5) unable to discontinue any medication with known
moderate or potent inhibitory eﬀect on CYP3A4, or is a substrate of
CYP3A4; (6) concomitant cytotoxic chemotherapy unless established on
maintenance treatment for > 6 weeks (not in a clinical trial); (7)
unable to understand written or spoken English.
2.2. Study design, objectives and sample size
The study was a two-centre, parallel group randomised controlled
phase II trial designed to assess whether the Src kinase inhibitor sar-
acatinib had eﬃcacy as an analgesic when compared to placebo using
cancer patients’ self-reported pain scores. The primary objective was to
determine if patients’ self-reported pain scores were signiﬁcantly lower
(pain score reduced by 2 or more on a 0–10 point scale) after 4 weeks of
treatment with saracatinib than with placebo, using questions 3 (worst
pain in last 24 h), 4 (least pain in last 24 h), 5 (average pain), and 6
(pain right now) of the Brief Pain Inventory - Short Form (BPI-SF [19]).
Secondary objectives were (i) to determine if concomitant analgesic
drug usage decreased with saracatinib; (ii) to determine if pain-related
symptoms and quality of life were improved by saracatinib using the
BPI-SF and the European Organisation for Research and Treatment of
Cancer QLQ-C30 (v 3.0) [20] and BM-22 [21] questionnaires; (iii) to
determine whether bone turnover was reduced by saracatinib in pa-
tients already taking bone anti-resorptive medications such as bispho-
sphonates or RANK ligand-inhibitors.
To determine if analgesic drug usage decreased when patients took
saracatinib, analgesic usage data for the previous 24 h period was
collected at screening and each clinic visit. The doses of all opioids were
converted to an overall equivalent dose of oral morphine (oral mor-
phine equivalent, OME). Oral morphine equivalent at the start of the
study was compared to OME at the end to determine whether this
changed whilst on treatment, the rationale being that if the study
medication provided additional pain relief then patients might reduce
their dose of other pain medications. Pain-related symptoms and
quality of life at the beginning and end of the study were compared
using summary data scores from the QLQ-C30 questionnaire and the
painful characteristics and painful sites scores from the QLQ-BM22
questionnaire. Bone turnover was assessed by measuring markers of
bone resorption (cross-linked C-terminal telopeptide of type I collagen,
sCTX; and cross-linked N-terminal telopeptide of type I collagen/crea-
tinine ratio; uNTX/Cr) and bone deposition (N-terminal propeptide of
type I procollagen (PINP) in either serum (sCTX, PINP) or urine (uNTX/
CR) samples [18].
For an exploratory study such as this, a group size of n=12 is
thought to be suﬃcient [22]. Using n=12/group and a population
standard deviation of 2.6 points in pain scores in patients with cancer
pain (AstraZeneca study D8180C00034, unpublished data) with a
minimally clinically important diﬀerence of 2-points [23] and a one-
sided signiﬁcance level of α = 10%, (acceptable as only a reduction in
pain scores was desirable and the study was exploratory) gives a power
of 72%. By comparison, a two-sided signiﬁcance level of α = 5% gives
only 50% power with the same group size.
2.3. Protocol
Patients that wished to participate in the study were screened to
ensure that they satisﬁed all of the inclusion criteria and none of the
exclusion criteria. Screening was done by experienced research nurses
7–14 days prior to randomization, and as well as conﬁrming eligibility
criteria, baseline samples for sCTx, PINP and uNTX/CR were taken and
the BPI-SF, EORTC QLQ-C30 and BM22 questionnaires administered.
To conﬁrm that baseline pain scores were within the eligibility criteria,
each potential recruit completed a daily BPI-SF questionnaire for 7 days
and mean pain scores calculated using question 5 (pain on average).
Patients that were eligible to enter the trial and who wished to parti-
cipate gave informed written consent and were randomized to either
saracatinib or placebo. Patients were randomized on a 1:1 basis using
block randomization with a block size of 4; the randomization schedule
was created by the company that prepared the treatment kits (Almac,
Craigavon, Northern Ireland, UK). Each randomized patient was
S. Danson, et al. Journal of Bone Oncology 19 (2019) 100261
2
assigned a unique code that was replicated on individual patient
treatment kits; the patient, the Investigator that randomized the patient
and the pharmacist that dispensed the treatment kit were all blinded to
the treatment assigned. Randomisation codes were assigned strictly
sequentially and if a subject withdrew from the study before completion
their randomization number could not re-used. At randomization a
venous blood sample was taken as a baseline for pharmacokinetic stu-
dies.
Patients randomized to saracatinib received 125mg once per day
for 28 days in tablet form. This dose of saracatinib is lower than the
maximum tolerated dose in patients with advanced solid malignancies
(175mg) and has an emerging safety proﬁle that was considered to be
acceptable for testing in this patient population with appropriate safety
monitoring during the trial [24]. Patients were advised to take a single
tablet at approximately the same time each day with food. Missed doses
were not to be ‘made-up’ and if a patient vomited after taking a tablet
the dose was not replaced. Compliance was assessed with a diary card
and by counting the remaining tablets in the bottle that was returned at
the end of treatment. Treatment was administered for 28 days unless:
(1) the patient asked to be withdrawn, (2) pain control deteriorated
during the trial requiring radiotherapy (3) the patient experienced
unacceptable adverse eﬀects. Treatment could be continued beyond 28
days of dosing at the discretion of the Investigator if the patient
received beneﬁt from treatment (average pain scores reduced by ≥2
points on a 0–10 scale) and there were no grade 3 or greater drug-
related adverse events.
Treatment commenced at randomization (day 1) and patients
completed the BPI-SF daily for 7 days after 1 week on study (days
8–14). At a clinic visit on day 15, performance status and haematolo-
gical/hepatic/renal function were checked to conﬁrm patients were still
eligible to participate. Blood and urine samples were taken for sCTX,
PINP, uNTX/Cr and pharmacokinetic testing and the BPI, EORTC QLQ-
C30 and BM22 questionnaires administered. Analgesic usage was re-
viewed, any changes since screening documented and OME calculated
for the previous 24 h. Adverse events were also documented. Patients
remained on treatment for 2 more weeks and completed the BPI-SF
daily during the last week of the study (days 22–28). A ﬁnal clinic visit
occurred on day 29; as before performance status and haematological/
hepatic/renal function were checked, blood and urine samples were
taken for sCTX, PINP and uNTX/Cr analysis, the BPI-SF, QLQ-C30 and
BM22 questionnaires administered and analgesic usage was reviewed,
any changes since screening documented and OME calculated for the
previous 24 h. Adverse events were also documented. A telephone in-
terview 30 days after the last clinic visit was performed to identify any
further adverse events that occurred after stopping treatment.
Fig. 1. Participant ﬂow diagram (CONSORT).
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2.3.1. Sample analysis
Blood samples for haematological, hepatic and renal function were
analysed immediately after collection for saracatinib safety monitoring;
samples for bone biomarker turnover and pharmacokinetic analysis
were prepared and frozen at -80 °C then analysed in batches. Serum (for
sCTX and PINP measurement) was prepared from venous blood that
was allowed to clot at room temperature for at least 30min, centrifuged
at 1300 g for 15min and aliquots frozen. Plasma (for pharmacokinetic
studies) was prepared by centrifuging venous blood collected in lithium
heparin tubes at 1000 g for 10 min within 30min of collection, ali-
quoted and frozen. Urine samples (1 mL volume, for uNTX/Cr) were
frozen until analyzed.
Saracatinib levels were measured in plasma samples using liquid
chromatography-mass spectrometry (Charles River, Tranent, UK) using
an ABI5000 mass spectrometer (AB Sciex, Ontario, Canada). The lower
limit of the assay was 0.5 ng/mL and the upper limit was 500 ng/mL.
Bone biomarkers were analysed as described previously [18].
3. Results
During the period September 2014–August 2017, 36 patients were
identiﬁed that were eligible to participate: 15 of these gave written
consent, 13 were randomized and 12 patients completed the study
(Fig. 1). The commonest reasons for eligible patients to decline parti-
cipation were the extra hospital visits required for the study and a 50%
chance of receiving placebo. The trial ended after 3 years when the
funding period ceased. Participants were allocated equally to the pla-
cebo and saracatinib groups and their demographics are shown in
Table 1. The commonest histology/primary site was adenocarcinoma of
the prostate (50%) and lytic lesions were the most frequent type of bone
metastases identiﬁed on imaging (56%; mixed lytic-sclerotic lesions
comprised 22% and sclerotic metastases were 22%). The commonest
site for bone metastases was the spine (50%) followed by the pelvis
(22%). Baseline average pain scores (BPI-SF question 5) from the
screening process showed comparable levels of background pain in the
placebo- and saracatinib-treated groups: placebo 5.0 ± 1.8 (mean ±
1 SD), saracatinib 5.2 ± 1.2, in keeping with moderate pain.
Patients randomized to saracatinib 125mg/day had plasma con-
centrations of drug in the range 80–190 ng/ml (mean: 148, S.D. 38);
this is comparable with other studies performed on this patient popu-
lation [2,38]. There was no detectable saracatinib in plasma samples
from any of the patients randomized to placebo.
3.1. Eﬃcacy of saracatinib as an analgesic for metastatic bone pain
Comparison of patients’ self-reported pain scores after 4 weeks of
treatment are shown in Table 2 for worst, least, average and current
pain (BPI-SF questions 3–6) and average pain scores for individual
patients (BPI-SF question 5) over the 4 weeks of the study are shown in
Fig. 2. As can be seen from Fig. 2, placebo-treated patients had no clear
trend in pain scores over time whereas for saracatinib-treated patients,
pain scores were either stable or reduced slightly over time (2/6 pa-
tients reported average pain scores reduced by ≥2, indicating a clini-
cally -signiﬁcant eﬀect in those individuals). When self-reported pain
ratings were compared (Table 2), the diﬀerence between placebo- and
saracatinib-treated groups after 4 weeks of treatment was not clinically
Table 1
Demographics of participants.
Placebo(n=6) Saracatinib(n=6)
Gender 2 female, 4 male 2 female, 4 male
Agea
(years)
57–71
(65 ± 5)
47–74
(61 ± 10)
Time since diagnosisb
(months)
4–123
(27)
2–64
(18)
Median number of bone metastases
(range)
3
(1–4)
3
(1–4)
Previous radiotherapy for bone pain
control
5/6 5/6
Primary tumour Breast = 1
Lung = 2
Prostate = 3
Breast = 2
Chordoma = 1
Prostate = 3
a Age at trial entry is given as the range (mean ± 1 S.D.).
b Number of months between diagnosis of bone metastasis and starting the
study is given as the range (median).
Table 2
Primary outcome.
Placebo(n=6) Saracatinib(n=6) Diﬀerence(95%
C.I.)
Worst pain in last 24 h
(Q3)
6.6 ± 2.3 6.0 ± 2.4 0.6
(-2.6 to 3.9)
Least pain in last 24 h
(Q4)
3.0 ± 3.1 3.2 ± 2.0 -0.2
(-2.5 to 3.2)
Average pain (Q5) 4.7 ± 2.6 4.3 ± 1.9 0.4
(-2.8 to 3.6)
Pain right now (Q6) 4.9 ± 2.6 4.5 ± 2.7 0.4
(-3.2 to 4.1)
Mean (±1 S.D.) pain scores for BPI-SF questions 3–6 after 4 weeks treatment
with either saracatinib (125mg/day) or placebo.
Fig. 2. Average pain scores during the study.
Patient-reported average pain scores (BPI-SF question 5, 0–10 scale) over the 4
weeks of treatment with either placebo (A) or saracatinib 125mg/day (B).
S. Danson, et al. Journal of Bone Oncology 19 (2019) 100261
4
signiﬁcant (< 2.0), regardless of which question was analysed. Similar
results were obtained when the amount of relief obtained by pain
medications was compared between the placebo- and saracatinib-
treated groups (data not shown).
On the basis of improvement in pain symptoms after 4 weeks of
treatment of at least 2 units on a 0–10 scale, 2 patients in the placebo-
treated group and 3 patients in the saracatinib-treated group went on to
extended use of study medication for up to 5 months. One of the sar-
acatinib-treated patients initially declined extended use, but later re-
quested extended use when her pain increased after the study ended. An
unblinded pharmacist ensured that patients on extended use continued
to receive the same medication that they were randomized to on day 1.
3.2. Eﬀect of saracatinib on background analgesic usage
There was wide variation in OME intake across patients, which was
due to the diversity of drugs that patients were prescribed for pain
management as well as inter-individual diﬀerences in dosing. In the
placebo-treated group mean OME at randomization was
130 ± 153 μg/day (range 3–340) and 138 ± 167 μg/day at the end of
the 4 week study (range 12 – 340). Equivalent ﬁgures for the sar-
acatinib treated group were 210 ± 352 μg/day at randomization
(range 18–920) and 207 ± 327 μg/day at the completion of the study
(range 5–860). The data indicate that 4 weeks of daily saracatinib
treatment at a dose of 125mg/day had no eﬀect on patients’ con-
sumption of regularly prescribed pain medication.
3.3. Eﬀects of saracatinib on quality of life
Quality of Life was assessed using 4 scores from the QLQ-C30 and
QLQ-BM22 questionnaires developed by the European Organisation for
Research and Treatment of Cancer [1,4]: C30 global health-related
Quality-of-Life, C30 pain items, BM22 painful sites items and the BM22
painful characteristics items. These data are shown in Table 3, and as
can be seen the diﬀerence between the mean scores between the pla-
cebo- and saracatinib-treated groups were small and unlikely to be
clinically -signiﬁcant.
3.4. Eﬀects of saracatinib on biomarkers of bone turnover
We studied two biomarkers of bone resorption, sCTX; and uNTX/Cr
and one biomarker of bone deposition, PINP. Four patients in the pla-
cebo-treated group had a history of anti-resorptive medication treat-
ment (three with bisphosphonates and one with the RANKL inhibitor
denosumab) and three of these continued to receive treatment during
the study (2 bisphosphate and 1 denosumab); in the saracatinib group 3
patients had a history of bisphosphonate treatment (including one who
also received denosumab) and two of them continued with bispho-
sphonate treatment during the study. Patients taking saracatinib
showed a signiﬁcant reduction in levels of serum CTX over time, with a
median reduction of 31% below baseline on day 29 (range 19–53%,
Fig. 3; p < 0.01, Kruskall–Wallis ANOVA). This eﬀect on bone
resorption is in keeping with the known action on osteoclasts of Src
inhibitors [17,18,25] and conﬁrms that saracatinib inhibited Src func-
tion clinically in this patient group. Both patients in the saracatinib-
treated group that were also taking concomitant bisphosphonates
showed reductions in serum CTX, of 34% and 19% below baseline,
indicating that saracatinib has potential to further reduce bone turn-
over in patients already taking anti-resorptive medication. There were
no eﬀects of saracatinib on urinary NTX/Cr ratio or on the bone for-
mation biomarker PINP (data not shown).
3.5. Safety
There were 45 reported adverse events during the study, 23 in the
placebo-treated group and 22 in the saracatinib-treated group. The
majority of adverse events were mild (83%) and needed observation
only and no intervention (CTC grade 1), 14% were grade 2 adverse
events and there was one grade 3 event that required hospitalization
(incoherence in a patient randomized to placebo; subsequently
Table 3
Eﬀects of saracatinib on Quality of Life measured with the QLQ-C30 and QLQ-BM22 questionnaires.
Placebo(n=6) Saracatinib(n=6) Diﬀerence(95% C.I.)
QLQ-C30, Global health-related Quality-of-Life score, day 29 69.1 ± 9.9 66.6 ± 10.0 2.5
(-16.79 to 21.84)
QLQ-C30, Pain score, day 29 61.1 ± 9.6 58.3 ± 17.5 2.8
(-18.8 to 23.3)
QLQ-BM22, painful characteristics score, day 29 38.9 ± 14.3 44.4 ± 0 -5.6
(-28.4 to 17.3)
QLQ-BM22 painful sites score, day 29 28.3 ± 12.6 36.0 ± 18.6 -3.9
(-26.4 to 18.6)
Note that higher Global Quality-of-Life scores indicate better Quality-of-Life, while higher pain-related scores reﬂect worse symptoms.
Fig. 3. Inhibition of bone resorption by saracatinib.
A. Changes in the bone resorption biomarker sCTX (serum cross-linked C-
terminal telopeptide of type I collagen) from baseline in individual patients
over 4 weeks of treatment; the dotted lines identify those patients that were also
receiving bisphosphonate treatment. B. mean ± 1 S.D. for both saracatinib and
placebo groups.
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diagnosed as progressive brain disease and unrelated to the study
medication). In the saracatinib-treated group, the majority of the ad-
verse events (73%) aﬀected the gastrointestinal system, with 13% being
neurological and 9% fatigue, in keeping with the known adverse event
proﬁle of saracatinib [26–39]. One patient experienced alopecia which
led to her stopping the trial.
4. Discussion
The current study showed that 4 weeks of treatment with sar-
acatinib did not have a clinically-signiﬁcant eﬀect on self-reported bone
pain scores in patients with symptomatic skeletal metastases. The lack
of analgesic eﬃcacy of saracatinib is unlikely to be due to inadequate
dosing, as plasma concentrations of drug were similar to published
phase I studies [24,40] and inhibition of Src kinase was achieved on the
basis of a signiﬁcant reduction in sCTX levels. In addition, a dose of
125mg saracatinib per day would be expected to give a drug con-
centration within cerebrospinal ﬂuid of about 10 nM, which is con-
sidered suﬃcient to inhibit Src kinase within the central nervous system
[40]. A limitation of this study was the small sample size per arm of the
study. There were signiﬁcant challenges in patient participation: only
half of the required number of patients recruited, and by necessity it
meant that a range of primary cancer types were studied. This limits the
conclusions that can be drawn from the study, and it should be regarded
as exploratory only.
Clinical studies support the contention that some of the pain
symptoms that are reported by patients with bone metastases are due to
changes in sensory processing within the central nervous system
[41,42]. Given this, our hypothesis was that saracatinib would exert
any potential analgesic activity it had by inhibiting Src activity within
the central nervous system (see Introduction). In neurons, Src is part of
the post-synaptic NMDA complex [10], but it is also enriched in os-
teoclasts [43] and platelets [44]. Our previous laboratory studies
showed in vivo inhibition of phosphorylation of the GluN1 subunit of
the NMDA receptor by saracatinib in a preclinical model of cancer-in-
duced bone pain; saracatinib also inhibited osteoclastic bone resorption
without aﬀecting osteoblastic bone formation [16]. The results from the
current study suggest that although saracatinib reduces bone resorp-
tion, either it has less impact than expected on NMDA receptor activity
in vivo, or that central sensitisation was not the dominant pain me-
chanism in the patients that were recruited. It is known that osteoclastic
inhibitors such as bisphosphonates have some analgesic eﬀect [45] and
inhibition of bone resorption using RANK ligand inhibitors (e.g. deno-
sumab [46]) or promoting bone formation with parathyroid hormone
(1–34) [47] can reduce pain from bone metastases and from osteo-
porotic vertebral fractures in patients. Compared to the bisphosphonate
zoledronic acid, denosumab delayed the development of severe pain
(scores ≥7 on a 0–10 scale) by about one month in patients with bone
metastases [46]. This is presumably due to the superior bone-preserving
eﬀect of denosumab versus zoledronic acid [48], as the time to the ﬁrst
skeletal-related event in a study of denosumab vs. zoledronic acid was 6
months longer for denosumab [46]. Saracatinib appears to have the
potential to inhibit tumour-related bone resorption in patients already
taking anti-resorptive agents, as shown in two patients here, and in the
future this might be an avenue that could be studied further.
As well as defects in pain processing [15] genetically-modiﬁed mice
that have the src gene deleted (Src−/−) show abnormal development of
bones and teeth with an osteopetrosis-like phenotype [49]. Multiple
genes have been implicated in the development of osteopetrosis in
humans and in rodents (see [50] for review), and the majority of the
proteins that these genes encode for relate to the function of a proton
ATPase and a chloride channel in the osteoclast ruﬄed membrane. The
likely mechanism of saracatinib-induced inhibition of bone resorption
is that Src controls the co-localization of the proton pump and the b
splice variant of the chloride intracellular channel protein 5 (CLIC-5b)
in osteoclasts [51] and inhibiting Src prevents channel co-localization
and reduces osteoclastic bone resorption. However, the only human
diseases that implicate abnormal Src function in their pathogenesis are
a subset of advanced colon cancers that were metastatic to the liver
[52] as well as thrombocytopenia-6 [53], and as yet there is no evi-
dence for a role of abnormal Src function in clinical pain in patients.
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